Medical - Healthcare Plans
Compare Stocks
4 / 10Stock Comparison
UNH vs MCK vs CVS vs CAH
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Distribution
Medical - Healthcare Plans
Medical - Distribution
UNH vs MCK vs CVS vs CAH — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Healthcare Plans | Medical - Distribution | Medical - Healthcare Plans | Medical - Distribution |
| Market Cap | $330.28B | $98.11B | $102.56B | $46.36B |
| Revenue (TTM) | $449.71B | $397.96B | $402.07B | $250.55B |
| Net Income (TTM) | $12.04B | $4.34B | $1.77B | $1.56B |
| Gross Margin | 18.8% | 3.4% | 13.8% | 3.7% |
| Operating Margin | 4.2% | 1.3% | 1.2% | 0.9% |
| Forward P/E | 19.9x | 20.5x | 11.3x | 19.1x |
| Total Debt | $78.39B | $7.39B | $93.59B | $9.35B |
| Cash & Equiv. | $24.36B | $5.69B | $8.51B | $3.87B |
UNH vs MCK vs CVS vs CAH — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| UnitedHealth Group … (UNH) | 100 | 119.4 | +19.4% |
| McKesson Corporation (MCK) | 100 | 504.8 | +404.8% |
| CVS Health Corporat… (CVS) | 100 | 123.1 | +23.1% |
| Cardinal Health, In… (CAH) | 100 | 360.2 | +260.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: UNH vs MCK vs CVS vs CAH
Each card shows where this stock fits in a portfolio — not just who wins on paper.
UNH has the current edge in this matchup, primarily because of its strength in quality and dividends.
- 2.7% margin vs CVS's 0.4%
- 2.4% yield, 25-year raise streak, vs CVS's 3.3%
MCK is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.
- Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
- 375.1% 10Y total return vs CAH's 175.5%
- 16.2% revenue growth vs CAH's -1.9%
- 5.3% ROA vs CVS's 0.7%, ROIC 5.4% vs 5.0%
CVS is the clearest fit if your priority is value.
- Lower P/E (11.3x vs 19.1x)
CAH is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 20 yrs, beta 0.03, yield 1.0%
- Lower volatility, beta 0.03, current ratio 0.94x
- Beta 0.03, yield 1.0%, current ratio 0.94x
- Beta 0.03 vs UNH's 0.59
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.2% revenue growth vs CAH's -1.9% | |
| Value | Lower P/E (11.3x vs 19.1x) | |
| Quality / Margins | 2.7% margin vs CVS's 0.4% | |
| Stability / Safety | Beta 0.03 vs UNH's 0.59 | |
| Dividends | 2.4% yield, 25-year raise streak, vs CVS's 3.3% | |
| Momentum (1Y) | +31.0% vs UNH's -7.9% | |
| Efficiency (ROA) | 5.3% ROA vs CVS's 0.7%, ROIC 5.4% vs 5.0% |
UNH vs MCK vs CVS vs CAH — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
UNH vs MCK vs CVS vs CAH — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
UNH leads in 1 of 6 categories
CVS leads 1 • MCK leads 1 • CAH leads 1 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
UNH leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UNH is the larger business by revenue, generating $449.7B annually — 1.8x CAH's $250.5B. Profitability is closely matched — net margins range from 2.7% (UNH) to 0.4% (CVS). On growth, MCK holds the edge at +11.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $449.7B | $398.0B | $402.1B | $250.5B |
| EBITDAEarnings before interest/tax | $23.2B | $5.8B | $9.3B | $3.2B |
| Net IncomeAfter-tax profit | $12.0B | $4.3B | $1.8B | $1.6B |
| Free Cash FlowCash after capex | $19.7B | $10.1B | $7.8B | $4.4B |
| Gross MarginGross profit ÷ Revenue | +18.8% | +3.4% | +13.8% | +3.7% |
| Operating MarginEBIT ÷ Revenue | +4.2% | +1.3% | +1.2% | +0.9% |
| Net MarginNet income ÷ Revenue | +2.7% | +1.1% | +0.4% | +0.6% |
| FCF MarginFCF ÷ Revenue | +4.4% | +2.5% | +1.9% | +1.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.0% | +11.4% | +8.2% | +11.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +0.7% | +38.2% | +76.9% | -19.5% |
Valuation Metrics
CVS leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 27.5x trailing earnings, UNH trades at a 53% valuation discount to CVS's 58.1x P/E. On an enterprise value basis, CVS's 12.5x EV/EBITDA is more attractive than MCK's 19.9x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $330.3B | $98.1B | $102.6B | $46.4B |
| Enterprise ValueMkt cap + debt − cash | $384.3B | $99.8B | $187.6B | $51.8B |
| Trailing P/EPrice ÷ TTM EPS | 27.50x | 31.14x | 58.05x | 30.54x |
| Forward P/EPrice ÷ next-FY EPS est. | 19.87x | 20.53x | 11.27x | 19.08x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.80x | — | — |
| EV / EBITDAEnterprise value multiple | 16.48x | 19.93x | 12.52x | 16.91x |
| Price / SalesMarket cap ÷ Revenue | 0.74x | 0.27x | 0.26x | 0.21x |
| Price / BookPrice ÷ Book value/share | 3.26x | — | 1.36x | — |
| Price / FCFMarket cap ÷ FCF | 20.55x | 18.77x | 13.14x | 25.06x |
Profitability & Efficiency
MCK leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
UNH delivers a 11.5% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $2 for CVS. UNH carries lower financial leverage with a 0.77x debt-to-equity ratio, signaling a more conservative balance sheet compared to CVS's 1.24x. On the Piotroski fundamental quality scale (0–9), UNH scores 6/9 vs CVS's 5/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +11.5% | — | +2.3% | — |
| ROA (TTM)Return on assets | +3.9% | +5.3% | +0.7% | +2.8% |
| ROICReturn on invested capital | +9.2% | +5.4% | +5.0% | +33.8% |
| ROCEReturn on capital employed | +9.7% | +30.5% | +6.1% | +19.2% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.77x | — | 1.24x | — |
| Net DebtTotal debt minus cash | $54.0B | $1.7B | $85.1B | $5.5B |
| Cash & Equiv.Liquid assets | $24.4B | $5.7B | $8.5B | $3.9B |
| Total DebtShort + long-term debt | $78.4B | $7.4B | $93.6B | $9.3B |
| Interest CoverageEBIT ÷ Interest expense | 4.71x | 25.04x | 1.68x | 6.38x |
Total Returns (Dividends Reinvested)
CAH leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MCK five years ago would be worth $43,011 today (with dividends reinvested), compared to $9,722 for UNH. Over the past 12 months, CAH leads with a +31.0% total return vs UNH's -7.9%. The 3-year compound annual growth rate (CAGR) favors CAH at 34.6% vs UNH's -7.7% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +8.8% | -2.6% | +2.4% | -3.7% |
| 1-Year ReturnPast 12 months | -7.9% | +13.7% | +24.2% | +31.0% |
| 3-Year ReturnCumulative with dividends | -21.4% | +121.2% | +25.3% | +144.1% |
| 5-Year ReturnCumulative with dividends | -2.8% | +330.1% | +11.9% | +240.3% |
| 10-Year ReturnCumulative with dividends | +217.0% | +375.1% | -2.2% | +175.5% |
| CAGR (3Y)Annualised 3-year return | -7.7% | +30.3% | +7.8% | +34.6% |
Risk & Volatility
Evenly matched — CVS and CAH each lead in 1 of 2 comparable metrics.
Risk & Volatility
CAH is the less volatile stock with a 0.03 beta — it tends to amplify market swings less than UNH's 0.59 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 94.8% from its 52-week high vs MCK's 80.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.59x | 0.04x | 0.05x | 0.03x |
| 52-Week HighHighest price in past year | $409.70 | $999.00 | $85.15 | $233.60 |
| 52-Week LowLowest price in past year | $234.60 | $637.00 | $58.35 | $137.75 |
| % of 52W HighCurrent price vs 52-week peak | +88.8% | +80.2% | +94.8% | +84.3% |
| RSI (14)Momentum oscillator 0–100 | 83.3 | 27.7 | 62.0 | 38.1 |
| Avg Volume (50D)Average daily shares traded | 8.1M | 690K | 7.3M | 1.6M |
Analyst Outlook
Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: UNH as "Buy", MCK as "Buy", CVS as "Buy", CAH as "Buy". Consensus price targets imply 26.7% upside for CAH (target: $250) vs 5.9% for UNH (target: $385). For income investors, CVS offers the higher dividend yield at 3.31% vs MCK's 0.34%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $385.43 | $1006.50 | $95.20 | $249.67 |
| # AnalystsCovering analysts | 52 | 31 | 41 | 33 |
| Dividend YieldAnnual dividend ÷ price | +2.4% | +0.3% | +3.3% | +1.0% |
| Dividend StreakConsecutive years of raises | 25 | 17 | 0 | 20 |
| Dividend / ShareAnnual DPS | $8.70 | $2.69 | $2.67 | $2.04 |
| Buyback YieldShare repurchases ÷ mkt cap | +1.7% | +3.2% | 0.0% | +1.7% |
UNH leads in 1 of 6 categories (Income & Cash Flow). CVS leads in 1 (Valuation Metrics). 2 tied.
UNH vs MCK vs CVS vs CAH: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is UNH or MCK or CVS or CAH a better buy right now?
For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.
2% revenue growth year-over-year, versus -1. 9% for Cardinal Health, Inc. (CAH). UnitedHealth Group Incorporated (UNH) offers the better valuation at 27. 5x trailing P/E (19. 9x forward), making it the more compelling value choice. Analysts rate UnitedHealth Group Incorporated (UNH) a "Buy" — based on 52 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — UNH or MCK or CVS or CAH?
On trailing P/E, UnitedHealth Group Incorporated (UNH) is the cheapest at 27.
5x versus CVS Health Corporation at 58. 1x. On forward P/E, CVS Health Corporation is actually cheaper at 11. 3x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — UNH or MCK or CVS or CAH?
Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +330.
1%, compared to -2. 8% for UnitedHealth Group Incorporated (UNH). Over 10 years, the gap is even starker: MCK returned +375. 1% versus CVS's -2. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — UNH or MCK or CVS or CAH?
By beta (market sensitivity over 5 years), Cardinal Health, Inc.
(CAH) is the lower-risk stock at 0. 03β versus UnitedHealth Group Incorporated's 0. 59β — meaning UNH is approximately 1630% more volatile than CAH relative to the S&P 500. On balance sheet safety, UnitedHealth Group Incorporated (UNH) carries a lower debt/equity ratio of 77% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — UNH or MCK or CVS or CAH?
By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.
2% versus -1. 9% for Cardinal Health, Inc. (CAH). On earnings-per-share growth, the picture is similar: Cardinal Health, Inc. grew EPS 87. 0% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, UNH leads at 11. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — UNH or MCK or CVS or CAH?
UnitedHealth Group Incorporated (UNH) is the more profitable company, earning 2.
7% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 2. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UNH leads at 4. 2% versus 1. 0% for CAH. At the gross margin level — before operating expenses — UNH leads at 18. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is UNH or MCK or CVS or CAH more undervalued right now?
On forward earnings alone, CVS Health Corporation (CVS) trades at 11.
3x forward P/E versus 20. 5x for McKesson Corporation — 9. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CAH: 26. 7% to $249. 67.
08Which pays a better dividend — UNH or MCK or CVS or CAH?
All stocks in this comparison pay dividends.
CVS Health Corporation (CVS) offers the highest yield at 3. 3%, versus 0. 3% for McKesson Corporation (MCK).
09Is UNH or MCK or CVS or CAH better for a retirement portfolio?
For long-horizon retirement investors, Cardinal Health, Inc.
(CAH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 03), 1. 0% yield, +175. 5% 10Y return). Both have compounded well over 10 years (CAH: +175. 5%, UNH: +217. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between UNH and MCK and CVS and CAH?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: UNH is a large-cap quality compounder stock; MCK is a mid-cap high-growth stock; CVS is a mid-cap income-oriented stock; CAH is a mid-cap quality compounder stock. UNH, CVS, CAH pay a dividend while MCK does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.